Drug Profile
UCB 6673
Alternative Names: UCB-6673Latest Information Update: 05 Mar 2019
Price :
$50
*
At a glance
- Originator Kings College London
- Class Immunotherapies; Peptides
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Immunological disorders; Type 1 diabetes mellitus
Most Recent Events
- 28 Feb 2019 UCB Pharma terminates its licence for UCB 6673 with King's College London before February 2019
- 28 Feb 2019 Discontinued - Phase-I for Immunological disorders in Belgium (unspecified route) before February 2019
- 28 Feb 2019 Discontinued - Preclinical for Type 1 diabetes mellitus in Belgium (unspecified route) before February 2019